Phase 1 Bladder Cancer Trial, Recruiting NCT05562791 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Bladder Cancer
Back to Bladder Cancer

Phase 1 Bladder Cancer Trial, Recruiting

NCT05562791
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the Bladder Cancer (Urothelial Carcinoma) group:

  • You have been diagnosed with bladder or urinary tract cancer that has spread beyond the pelvis to areas such as the lungs, liver, bones, or other tissues, confirmed by a tissue biopsy
  • You have at least one area of cancer that can be seen and measured on a special type of scan called a PET/CT scan, identified as suspicious by a specialist doctor at MSKCC
  • You are well enough to carry out some daily activities (a doctor will assess your general health using a standard scale)
  • You are 18 years of age or older
  • You are able to understand and are willing to sign a consent form agreeing to take part

For the Melanoma group:

  • You have been diagnosed with melanoma (a type of skin cancer) that has spread to other parts of the body, confirmed by a tissue biopsy
  • You have at least one area of cancer that can be seen and measured on a CT or PET/CT scan, identified as suspicious by a specialist doctor at MSKCC
  • You are well enough to carry out some daily activities (a doctor will assess your general health using a standard scale)
  • You are 18 years of age or older
  • You are able to understand and are willing to sign a consent form agreeing to take part

Who may not be able to join:

For the Bladder Cancer (Urothelial Carcinoma) group:

  • Your cancer has only spread to lymph nodes within the pelvis, with no spread outside that area
  • Your cancer has only spread to the bones, with no other areas affected
  • You are unable to lie flat and stay still long enough to complete a PET scan
  • You are currently being treated for a different type of cancer (except certain minor skin cancers that have not spread)
  • You are already taking part in another treatment trial where having a PSMA imaging scan could affect that trial's results
  • You are being monitored (but not treated) for a different cancer you have been diagnosed with previously
  • You are pregnant, or if you could become pregnant, you do not have a recent negative pregnancy test on record

For the Melanoma group:

  • You are unable to lie flat and stay still long enough to complete a PET scan
  • You are already taking part in another treatment trial where having a PSMA imaging scan could affect that trial's results
  • You are pregnant, or if you could become pregnant, you do not have a recent negative pregnancy test on record

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gopakumar Iyer, Memorial Sloan Kettering Cancer Center

Phone: 646-888-4737

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
28 September 2022
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Define the proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT for Urothelial Carcinoma; Define the proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT for Melanoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov